CoChat

Corticosteroid Therapy in IgA Nephropathy

Open access

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Abstract

The benefits and risks of steroids for the treatment of IgA nephropathy remain uncertain. We systematically searched MEDLINE, EMBASE, and the Cochrane Library for randomized, controlled trials of corticosteroid therapy for IgA nephropathy published between 1966 and March 2011. We identified nine relevant trials that included 536 patients who had urinary protein excretion >1 g/d and normal renal function. Forty-six (8.6%) of these patients developed a kidney failure event, defined as doubling of the serum creatinine/halving of the GFR or ESRD. Overall, steroid therapy was associated with a lower risk for kidney failure (relative risk, 0.32 [95% confidence interval [CI], 0.15-0.67]; P=0.002) and a reduction in proteinuria (weighted mean difference, -0.46 g/d [95% CI, -0.63 to -0.29 g/d]), with no evidence of heterogeneity in these outcomes. Subgroup analysis suggested that the dose modifies the effect of steroids for renal protection (P for heterogeneity=0.030): Relatively high-dose and short-term therapy (prednisone >30 mg/d or high-dose pulse intravenous methylprednisolone with duration ≤1 year) produced significant renal protection, whereas low-dose, long-term steroid use did not. Steroid therapy was associated with a 55% higher risk for adverse events. The quality of included studies was low, however, limiting the generalizability of the results. In conclusion, steroids appear to provide renal protection in patients with IgA nephropathy but increase the risk for adverse events. Reliably defining the efficacy and safety of steroids in IgA nephropathy requires a high-quality trial with a large sample size.

Overview

Integrity signals

Registry

Crossref · 10.1681/asn.2011111112

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 190

Metadata

Authors
Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H.
Affiliations
  • Peking University (CN)
  • The University of Sydney (AU)
  • The University of Queensland (AU)
  • University of British Columbia (CA)
Corresponding author
  • Lv, Jicheng
  • Xu, Damin
  • Ma, Xinxin
  • Zhang, Hong
  • Wang, Haiyan
Venue
Journal of the American Society of Nephrology
Published
2012-06
Volume
23
Issue
6
Pages
1108-1116
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2107238505
Cited by
190
References
33
Citations by year
2026: 3 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 12 · 2021: 13 · 2020: 13 · 2019: 13 · 2018: 16 · 2017: 24 · 2016: 22 · 2015: 16 · 2014: 13 · 2013: 13 · 2012: 2
FWCI
11.11
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Society of Nephrology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
IgA nephropathy, corticosteroid therapy, prednisone, methylprednisolone pulse therapy, proteinuria, renal failure, renal protection, adverse events
MeSH terms
Administration, Oral, Adrenal Cortex Hormones, China, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glomerulonephritis, IGA, Humans, Infusions, Intravenous, Kidney Failure, Chronic, Kidney Function Tests, Male, Methylprednisolone, Prednisone, Prognosis, Severity of Illness Index, Survival Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Disease-Free Survival, Pulse Therapy, Drug

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Corticosteroid Therapy in IgA Nephropathy. https://app.cochat.ai/papers/10.1681/asn.2011111112
The paper
Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H. (2012). Corticosteroid Therapy in IgA Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2011111112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.